

Development of ‘Best-in-Class’ IL-2 for Solid Tumor Treatments



ONCOLOGY	Hit
Product Type	Heterodimeric Fc fusion protein
Indication	Metastatic Renal cell carcinoma (mRCC) Metastatic Melanoma (mM)
Target	Teff/NK cell
MoA (Mechanism of Action)	Selective binding to IL-2R $\beta\gamma$, but not to IL-2R α → Selective activation of IL-2R $\beta\gamma$ on cancer-killing Teff cells to enhance its efficacy, as well as safety
Competitiveness	<ol style="list-style-type: none"> 1. Improved efficacy & safety via Teff selectivity 2. Longer half life via NuvoFcTM (Genuv's own Fc platform) 3. Better 'develop-ability' (easy to manufacture)
Development Stage	Hit
Route of Administration	Parenteral intravenous